## 2003 DRAFTING REQUEST

## Senate Amendment (SA-SR(LRBx4402/1))

Received: 03/04/2004	Received By: pdykman			
Wanted: Today	Identical to LRB:			
For: Judith Robson (608) 266-2253	By/Representing: Soderbloom, Kathy			
This file may be shown to any legislator: NO	Drafter: pdykman			
May Contact:	Addl. Drafters:			
Subject: Memorials - to Congress	Extra Copies: DAK			
Submit via email: <b>YES</b>				
Requester's email: Sen.Robson@legis.state.wi.us				
Carbon copy (CC:) to:				
Pre Topic:				
No specific pre topic given				
Topic:				
two more whereas				
Instructions:				
See Attached Whereas, pharmaceutical companies' after-tand development - averaged 17% from 1994 to 1998, comp. Whereas, pharmaceutical companies spent \$15.7 billion in 2000 protected from competition by current law; and Whereas, pharmaceutical companies from 1993-1996 paid an a	oared with 5% for all other industries; and 0 on product promotion despite being			

**Drafting History:** 

Vers. **Drafted** Reviewed **Typed** Proofed **Submitted Jacketed** Required

Whereas, pharmaceutical companies from 1993-1996 paid an average effective tax rate of 16.2%, compared

to all other major industries who paid an average effective tax rate of 27.3%; and

Vers.	<u>Drafted</u>	Reviewed	Typed	Proofed	Submitted	<u>Jacketed</u>	Required
/? /1	pdykman 03/04/2004	csicilia 03/04/2004	rschluet 03/04/2004	1	sbasford 03/04/2004	sbasford 03/04/2004	

FE Sent For:

<**END>** 

### 2003 DRAFTING REQUEST

### Senate Amendment (SA-SR(LRBx4402/1))

Received: 03/04/2004 Received By: pdykman

Wanted: **Today** Identical to LRB:

For: Judith Robson (608) 266-2253 By/Representing: Soderbloom, Kathy

This file may be shown to any legislator: NO Drafter: pdykman

May Contact: Addl. Drafters:

Subject: Memorials - to Congress Extra Copies: DAK

Submit via email: **YES** 

Requester's email: Sen.Robson@legis.state.wi.us

Carbon copy (CC:) to:

#### **Pre Topic:**

No specific pre topic given

**Topic:** 

two more whereas

#### **Instructions:**

See Attached Whereas, pharmaceutical companies' after-tax profits - and after expenditures for research and development - averaged 17% from 1994 to 1998, compared with 5% for all other industries; and Whereas, pharmaceutical companies spent \$15.7 billion in 2000 on product promotion despite being protected from competition by current law; and

Whereas, pharmaceutical companies from 1993-1996 paid an average effective tax rate of 16.2%, compared to all other major industries who paid an average effective tax rate of 27.3%; and

### **Drafting History:**

<u>Vers.</u> <u>Drafted</u> <u>Reviewed</u> <u>Typed</u> <u>Proofed</u> <u>Submitted</u> <u>Jacketed</u> <u>Required</u>

/? pdykman / 45 3/4



# State of Misconsin 2003 - 2004 LEGISLATURE

LRBa2575/1
PJD:../:...

## SENATE AMENDMENT,

# TO 2003 SENATE RESOLUTION (LRB-4402/1)

Moond

. 1	At the locations indicated, amend the resolution as follows:
2	1. Page 2, line 13: after that line insert:
3	"Whereas, pharmaceutical companies' after-tax profits, after expenditures for
4	research and development, averaged $17\%$ from 1994 to 1998, compared with $5\%$ for
5	all other industries; and epercent percent
6	Whereas, pharmaceutical companies spent \$15.7 billion in 2000 on product
7	promotion despite being protected from competition by current law; and
8	Whereas, pharmaceutical companies from 1993 (1996 paid an average effective
9	tax rate of 16.2%, compared to all other major industries, who paid an average
10	effective tax rate of 27.3%; and".
11	(END)
	percent